• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Almac Group

    Adare Pharma Solutions

    PCI Pharma Services

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Emergent BioSolutions

    Reed-Lane

    Quotient Sciences

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    CMOs Demanding More Innovations

    Chromatography and single-use equipment top list

    Eric Langer , BioPlan Associates11.13.13
    Contract manufacturing organizations (CMOs) are always on the lookout for new ways to optimize efficiency in order to differentiate themselves from the competition. This often puts them on the leading edge of innovation in products and services.

    So in a sense, taking stock of CMO views regarding which new product development areas are most in demand can give insights into how the overall technology segment and market may evolve. In addition, because CMOs need to run far more varied campaigns, and must operate under constant cost pressures, following the CMOs lead can also provide some perspectives on which new technologies may have the greatest potential for contributing to future improvements. Essentially, since they have the most at stake, if CMOs see a technology as a good idea, it may be a good bet.

    In our 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production1 we examined new product development areas most desired by CMOs and compared them to biotherapeutic developers’ interests. We found some substantial differences in preference between the two groups.

    For CMOs, the top area in demand for better innovation is in downstream processing; this also correlates to where the industry is experiencing problems. Specifically, disposable purification products top the list. Here, 61.1% of CMOs want their suppliers to focus their development efforts on better products. Interestingly, only half that number of biodevelopers (30%) feels the same away, with disposable purification products ranking fourth among that group. The interest among CMOs in single-use (plastic) devices also relates to that segment’s need for flexible manufacturing, multiple campaigns, and technologies that speed up project turnaround.

    Second on the list among CMOs are disposable bags and connectors and process development (downstream) services, each cited by 39% of respondents. The former was the top area in demand among biodevelopers (by 44%), while the latter was in the fifth spot among developers, cited by 29%.

    Despite sharing similar levels of desire for innovation in disposable bioreactors (roughly one-third of each group wants their suppliers to focus their efforts there), CMOs and biodevelopers show some significantly different priorities for:
    • Disposable probes and sensors (27.8% for CMOs; 41.3% for biodevelopers);
    • Process development (downstream) services (33.3% for CMOs; 25.4% for biodevelopers);
    • Analytical development (also 33.3% for CMOs and 25.4% for biodevelopers).


    Fig. 1: Selected new product development areas of interest: Biotherapeutic Developers vs. CMOs
    We also found that CMOs expressed much higher interest in Design of Experiment (DoE) compared to product developers. CMOs are presumably involved in designing more bioprocesses with clients seeking state-of-the-art DoE to satisfy FDA expectations. And with DoE methodologies not standardized, each company designing a bioprocess needs to only consider its approach to DoE once, as each product moves through development. In contrast, CMOs have to deal with diverse companies, with DoE approaches varying with every single client and product they are involved with.

    It’s somewhat less surprising that biomanufacturers are generally more interested in innovative analytical assays than CMOs. Separately, we found a similar skew when we asked respondents to identify which of a list of assays needed improved testing methods most urgently for biomanufacturers.

    Overall, biopharma developers reported higher desires for improved assays for the majority of the areas we queried. For example, they were more likely than CMOs to see an urgent need for new or improved testing methods in:
    • Aggregation
    • Better stability assays
    • Glycosylation
    • Biophysical characterization during process development


    Fig. 2: Selected factors in biomanufacturing performance creating “Significant” or “Some” improvements, Biomanufacturers vs. CMOs
    There were a few standout areas, though, in which CMOs clearly see a need for improvement. First among those was biotech drug comparability (for in-house manufacturing changes as well as biosimilars), for which 56% of CMOs recognize a need for new or improved testing methods, compared to 39% of biodevelopers. CMOs are also seeking progress in bioassays of proteins with multiple functional domains, cited by exactly half of the CMO respondents, compared to 29% of biodevelopers.

    Although relatively few respondents from either group singled out disposable pH as an assay area in urgent need of improvement, pH sensors appear to be more in need of improvement than any others, according to separate results from our survey. (When we asked disposables users which of a number of single-use sensors they would like to see introduced or improved, pH topped the list, ahead of dissolved oxygen, cell density, CO2, glucose and in-line titers.)

    Biomanufacturers More Focused on Upstream than Downstream
    As mentioned, disposable purification equipment is the innovation area that CMOs are most interested in. With all the recent improvements in upstream titers, downstream purification has become a bottleneck preventing greater capacity utilization. One would expect that demand for new, innovative solutions in this area would be high — but it does not yet seem to be a focus for biodevelopers.

    Conversely, it appears that biomanufacturers continue to be more focused on upstream innovations than CMOs — and one explanation may be that they appear to be getting more out of improvements in that area.

    Separately in our study we asked respondents to indicate which factors have created “significant” or “some” improvements in biomanufacturing performance at their facility during the past 12 months. Among biomanufacturers, the top factor was “improved upstream production operations,” cited by almost three-quarters (74%) as creating improvements. The same factor was cited by 61% of CMOs, good only for the seventh position out of the 15 factors we identified.

    CMOs reported relatively greater performance improvements in many other areas queried. The most significant differences reported concerned:
    • Better Design of Experiments (DoE), related to process development
    • More automated control of processes
    • Better plant design
    With CMOs generally developing more bioprocesses (products) and with efficiency in operations (profitability) being a major concern, this presumably results in more effort being directed at implementing improved process design and control and overall plant integration. CMOs are clearly reporting more improvements in these areas. Also, as previously noted, with CMOs involved with more products/bioprocesses, they have more opportunities to see trends for improvement from such things as implementing DoE, more process automation and better plant design.

    Overall, the top areas for improvements now involve process development, operations and control. This is in line with the industry’s continuing concentration on increasing productivity, particularly in manufacturing. It was surprising to see the varied responses to these questions between product developers and CMOs, with the product manufacturers reporting more frequent implementation of process-related improvements. One might typically expect CMOs, with their high project turnover and need to do it right quickly and the first time, to be out in front of product manufacturers in terms of implementing process improvements. Perhaps, we are seeing the result of increased FDA concerns and fallout from major pharma manufacturing failures, with these publicized problems placing more demands on product manufacturers and FDA. CMOs remain predominantly involved in smaller-scale R&D and clinical supplies manufacture, where regulatory manufacturing-related requirements are less strict. And there have been few recent prominent reports of biopharma CMO manufacturing failures, with product developers/manufacturers being the ones primarily affected by FDA inspection and other quality failures.

    Cost is a Concern for CMOs
    Our data shows that for the time being, CMOs are less focused on innovations on the upstream side. That may be the result of the biotherapeutic developer’s business model, which is focused on scaling up fewer products in-house, and therefore has more flexibility to implement new products and otherwise optimize bioprocessing. Nevertheless, as the industry begins to adopt more modular, flexible biomanufacturing facilities, we will likely see a greater focus among both groups on disposables innovation — whether upstream or downstream.

    Cost may present a short-term hindrance for CMOs, though. As part of our broad industry study, we asked respondents the key areas to address in order to avoid future capacity constraints. Our results showed that CMOs were, not unexpectedly, more focused than developers on more cost-effective disposable, single-use products (47% vs. 36%). It’s interesting to see CMOs more focused on cost-effective disposable products; CMOs appear to be relatively satisfied with the performance of single-use products, but they’re not as happy with the cost of those devices.

    Other results from our study support those findings. When we asked biodevelopers and CMOs the single most important reason for not increasing use of disposable technologies, fully 20% of CMOs cited their high cost, compared to only 4.3% of developers. In fact, cost lagged only concerns surrounding leachables and extractables (also the top concern for biodevelopers) as the most important reason for CMOs to not increase their use of disposables.

    Into the Future
    The biopharma industry is evolving and demanding new and improved bioprocessing technologies to reduce costs, increase efficiencies, and improve weak development pipelines. Many large pharma companies today are devoting development efforts on biologics rather than small molecule drugs. In fact, most are now spending 40% or more of their R&D on biopharmaceuticals. To facilitate this trend, innovation into improved productivity continues unabated and is a primary driver for many of the current biopharma trends.

    For CMOs, desire for innovation will likely surround the key question: Which expression systems, or single-use manufacturing will reduce long-term production costs? Some of the trends we see in our industry studies support a future vision that includes:
    • Increasing number of global biopharma facilities2
    • More biological products, many with smaller niches
    • More multi-product facilities
    • More single use systems at clinical and commercial scale
    • Continuous processing, including perfusion
    • High-tech expression systems and other genetic engineering advances
    • Modular facilities adaptable to new enabling technologies
    We would expect to see increasingly rapid adoption, among CMOs and biotherapeutic developers, of single-use systems for the majority of new commercial manufacturing facilities during the next five years, and we similarly expect continuous bioprocessing to follow a similar trajectory. Use of these products is likely to further increase with hybrid systems that use bolt-on-type technology to retrofit components unit operations for existing systems. Other conventional technologies adaptable to continuous use, such as centrifugation, will also enjoy increasing adoption in coming years.

    CMOs are already at the forefront of disposables adoption. Will they be on the leading edge of the move to modular, flexible facilities, too? 

    References
    1. 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates,  April 2013.
    2. BioPlan’s Global Facilities Website www.top1000bio.com

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc. (bioplanassociates.com), a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing,” and other industry reports. He can be reached at elanger@bioplanassociates.com and 301-921-5979. 

    Survey Methodology: The 2013 Tenth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production yields a composite view and trend analysis from 238 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 30 countries. The methodology also included over 158 direct suppliers of materials, services and equipment to this industry. This year's study covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world's major markets in the U.S. and Europe.
    Related Searches
    • Pharma
    • Stability
    • Manufacturing
    • contract manufacturing organizations

    Related Bio News & Views

    • Biosimilars | Process Development
      Biopharm Executives Point to Better CMO Performance

      Biopharm Executives Point to Better CMO Performance

      Better process control and increased adoption of single-use systems played a part in improving downstream manufacturing
      Eric S. Langer, BioPlan Associates, Inc. 10.14.14

    • Biosimilars | Logistics | Supply Chain | Validation

      Outsourcing Media and Buffer Prep

      Facilities are evaluating ways to reduce bottlenecks, lower risks, eliminate logistics and inventory costs
      Eric S. Langer, BioPlan Associates, Inc. 09.08.14

    • Biosimilars | Clinical Trials | Drug Delivery | Fill/Finish

      Alvotech and Finesse Enter Bio-Manufacturing Pact

      Catalent, CiRA in regenerative therapy pact
      04.03.14


    • Biosimilars | cGMP Manufacture | Toxicology

      Too Much CMO Capacity?

      ...
      Eric A. Langer, BioPlan Associates 03.07.14

    • Biosimilars | Validation
      Bio-CMO Capacity Constraints

      Bio-CMO Capacity Constraints

      What they’re doing about them
      Eric Langer, BioPlan Associates 09.05.13

    • Biologics, Proteins, Vaccines | Capsules | Clinical Trial Materials | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Parenterals | Process Development | QA/QC | Validation

      How Far Do You Go?

      ...
      Victor A Vinci, Ph.D., Cook Pharmica 06.05.13


    • Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Scale-up/Technology Transfer
      Future Bio-Capacity Constraints

      Future Bio-Capacity Constraints

      Top 10 factors from a new survey
      Eric S. Langer, BioPlan Associates, Inc. 09.06.12

    • Analytical Services | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Capsules | Cleaning Validation | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Process Development | Process Validation | Regulatory Affairs | Scale-up/Technology Transfer | Toxicology | Validation

      The FDA Says You Are Responsible

      . . . But do you know who you are?
      E. Morrey Atkinson, Ph.D., Cook Pharmica 05.04.12

    • Bio News | Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development
      Industry Adopting More Complex Devices

      Industry Adopting More Complex Devices

      CMOs are spending twice as much as bio-innovators on single-use devices
      Eric S. Langer, BioPlan Associates, Inc. 03.07.12


    • Biologics, Proteins, Vaccines | Capsules | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | R&D | Scale-up/Technology Transfer

      Whose Platform Is It Anyway?

      Both Sides of the Table
      E. Morrey Atkinson, Ph.D. 01.23.12

    • Biologics, Proteins, Vaccines | Extractables and Leachables | Facilities | GMPs/GCPs | Methods Development | Process Development | Process Validation | QA/QC | Validation

      Why Not Do an Engineering Lot?

      Both Sides of the Table – A discussion of CMO/client perspectives
      E. Morrey Atkinson. Ph.D. 10.11.11

    • Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Scale-up/Technology Transfer | Validation
      Bio-Outsourcing On the Rise

      Bio-Outsourcing On the Rise

      Fewer companies go 100% in-house
      Eric S. Langer 09.07.11


    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login